HIMS BREAKING NEWS: Hims & Hers Health, Inc. is being Investigated for Securities Fraud; Investors with Losses are Notified to Contact BFA Law

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws.

If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.

Why is Hims & Hers being Investigated?

Hims & Hers is a telehealth company that provides consumers access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” through which Hims & Hers would sell Novo Nordisk’s popular weight loss drug Wegovy.

The Stock Declines as the Truth is Revealed

On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in “deceptive marketing” and the illegal “selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” On this news, the price of Hims & Hers stock fell $22.25 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025.

Click here for more information: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.

What Can You Do?

If you invested in Hims & Hers you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action

Attorney advertising. Past results do not guarantee future outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250623864704/en/